Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors

Core Viewpoint - Viatris Inc. is undergoing a Board refreshment process, announcing the retirement of directors Rajiv Malik and Harry Korman, and the appointment of Frank D'Amelio and Michael Severino, M.D. to its Board of Directors [1][7][10] Group 1: Board Changes - Frank D'Amelio and Michael Severino, M.D. have been appointed as new members of Viatris' Board of Directors [1][2] - Rajiv Malik and Harry Korman will retire from the Board at the end of their current terms in December 2025 [1][10] Group 2: New Board Members' Background - Frank D'Amelio has 20 years of experience as a public company CFO, most recently at Pfizer, where he oversaw corporate finance functions and global supply during the COVID-19 pandemic [3][4] - Michael Severino, M.D. is currently the CEO of Tessera Therapeutics and has held significant roles at AbbVie and Amgen, focusing on drug development and management [5][6] Group 3: Statements from Leadership - Melina Higgins, Chair of Viatris' Board, expressed enthusiasm for the new appointments, highlighting their extensive experience in the pharmaceutical industry [7] - Scott A. Smith, CEO of Viatris, emphasized the value of D'Amelio's financial expertise and Severino's drug development background for the company's future [7][8] Group 4: Company Overview - Viatris Inc. is a global healthcare company that aims to bridge the gap between generics and brands, providing access to high-quality medicines for approximately 1 billion patients annually [9]